ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
DITEST™- Oral Native Testosterone
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 209966" data-attributes="member: 13851"><p>[URL unfurl="true"]https://www.stockmarketwire.com/article/7218396/Diurnal-to-submit-new-drug-application-for-hypogonadism-treatment-to-FDA-in-Q4.html[/URL]</p><p></p><p><strong>Diurnal to submit new drug application for hypogonadism treatment to FDA in Q4</strong></p><p><strong></strong></p><p><strong>11 October 2021 | 08:50am</strong></p><p></p><p><a href="https://www.stockmarketwire.com/" target="_blank">StockMarketWire.com</a> - <em>Pharmaceutical company Diurnal said it would submit a new drug application to the US Food and Drug Administration in the fourth quarter for its male hypogonadism treatment.</em></p><p><em></em></p><p><em>Results from its phase 1 clinical trial for its oral testosterone formulation Ditest to treat male primary and secondary hypogonadism have been published in the peer-reviewed European Journal of Endocrinology.</em></p><p><em></em></p><p><em><strong>Ditest demonstrated the achievement of testosterone levels within the healthy young male adult normal range after oral administration.</strong></em></p></blockquote><p></p>
[QUOTE="madman, post: 209966, member: 13851"] [URL unfurl="true"]https://www.stockmarketwire.com/article/7218396/Diurnal-to-submit-new-drug-application-for-hypogonadism-treatment-to-FDA-in-Q4.html[/URL] [B]Diurnal to submit new drug application for hypogonadism treatment to FDA in Q4 11 October 2021 | 08:50am[/B] [URL='https://www.stockmarketwire.com/']StockMarketWire.com[/URL] - [I]Pharmaceutical company Diurnal said it would submit a new drug application to the US Food and Drug Administration in the fourth quarter for its male hypogonadism treatment. Results from its phase 1 clinical trial for its oral testosterone formulation Ditest to treat male primary and secondary hypogonadism have been published in the peer-reviewed European Journal of Endocrinology. [B]Ditest demonstrated the achievement of testosterone levels within the healthy young male adult normal range after oral administration.[/B][/I] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
DITEST™- Oral Native Testosterone
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top